Olistico Wealth LLC Reduces Position in Novo Nordisk A/S $NVO

Olistico Wealth LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 74.5% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 755 shares of the company’s stock after selling 2,207 shares during the quarter. Olistico Wealth LLC’s holdings in Novo Nordisk A/S were worth $52,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. bought a new position in Novo Nordisk A/S in the first quarter valued at about $27,000. Stone House Investment Management LLC purchased a new position in Novo Nordisk A/S in the first quarter worth about $30,000. Disciplina Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 297 shares during the period. Finally, Spirit of America Management Corp NY bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $35,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.6%

NVO stock opened at $59.68 on Friday. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $120.56. The firm’s 50-day moving average is $54.92 and its 200 day moving average is $63.73. The company has a market capitalization of $266.45 billion, a PE ratio of 16.39, a P/E/G ratio of 2.28 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is currently 22.53%.

Analysts Set New Price Targets

A number of research firms recently issued reports on NVO. Hsbc Global Res raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Barclays restated an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Finally, TD Cowen lowered their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $77.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.